Zipalertinib
Taiho Oncology / Cullinan Therapeutics (CGEM)
Decision dateFeb 27, 2027
104 days away
Marketer take
Would enter EGFR exon 20 insertion lung cancer, a niche where amivantamab-based regimens are established, so biomarker testing rates and thoracic oncologist reach set the size of the opportunity.
- Sponsor company
- Taiho Oncology / Cullinan Therapeutics (CGEM)
- Indication
- Relapsed EGFR exon 20 insertion non-small cell lung cancer
- Therapeutic area
- Oncology
- Event
- PDUFA target action date
- Date
- Feb 27, 2027
- Status
- Upcoming
- Source
- company press release
- Last verified
- Nov 15, 2026
Dates and status come from the linked public source as of the last verified date. Spot an error or have an update?